Welcome to our dedicated page for ProKidney news (Ticker: PROK), a resource for investors and traders seeking the latest updates and insights on ProKidney stock.
ProKidney Corp (NASDAQ: PROK) is a clinical-stage biotechnology leader developing autologous cellular therapies for chronic kidney disease. This page provides centralized access to official company announcements, clinical trial updates, and strategic developments.
Investors and researchers will find timely updates on PROK's REACT therapy progress, including Phase 3 trial results, regulatory interactions with the FDA/EMA, and manufacturing advancements. Our news collection features earnings reports, partnership announcements, and scientific presentations - all essential for understanding the company's position in regenerative medicine.
The repository includes:
- Clinical trial milestones and data readouts
- Regulatory submissions and designations (including RMAT status)
- Financial performance updates
- Strategic collaborations in nephrology research
- Peer-reviewed study publications
Bookmark this page for verified updates about ProKidney's innovative approach to preserving kidney function through cellular therapy. Check regularly for new developments in this rapidly evolving therapeutic area.
ProKidney Corp. (Nasdaq: PROK) announced its fourth quarter 2022 financial results, reporting a net loss of $24.6 million, compared to $13.7 million in Q4 2021. The company has made significant strides in clinical development, particularly in its REACT® trials for chronic kidney disease, with key milestones anticipated in 2023. Their cash position stands at $490.3 million, bolstered by a PIPE financing that raised over $500 million. R&D expenses rose to $20.9 million, driven by intensified clinical activities. G&A expenses also increased to $9.3 million, influenced by public company costs. The company expects to fund operations through 2024, aiming for topline data from proact1.
ProKidney Corp. (Nasdaq: PROK), a leader in cellular therapeutics for chronic kidney disease (CKD), announced that CEO Dr. Tim Bertram will present at TD Cowen’s 43rd Annual Health Care Conference on March 7, 2023, at 10:30 AM EST. Investors can access the live webcast on ProKidney’s investor relations site. The company’s groundbreaking product, REACT™, is a patented therapy aimed at treating late-stage CKD, having received Regenerative Medicine Advanced Therapy designation and FDA guidance. ProKidney, founded in 2015, highlights the critical need for effective CKD treatments, given the high mortality rates associated with late-stage CKD.
FAQ
What is the current stock price of ProKidney (PROK)?
What is the market cap of ProKidney (PROK)?
